Intercept Pharma net loss widens in Q4 and FY16

• Intercept Pharmaceuticals (NASDAQ:ICPT -3.6%) Q4 results: Revenues: $13.8M; Operating Loss: ($114M) (-28.2%); Net Loss: ($120M) (-35.9%); Loss Per Share: ($4.84) (-33.7%).
• 2016 results: Revenues: $25M; Operating Loss: ($402.5M) (-75.6%); Net Loss: ($412.8M) (-82.3%); Loss Per Share: ($16.74) (-75.1%); Quick Assets: $689.4M (+9.8%).
• 2017 Guidance: Non-GAAP Operating Expenses: $380M - 420M.